MARTINSRIED / MUNICH, Germany, Sept. 12, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced the appointment of four leading experts to its newly formed Scientific Advisory Board (SAB). The SAB is set up to consult the Company with regard to strategic options and future perspectives within its research and development activities. The goal of the SAB is thus to further strengthen MorphoSys's leadership position in discovery and clinical development of antibody and peptide-based therapies for cancer, inflammation and other therapeutic fields of high medical need.
The inaugural members of MorphoSys's Scientific Advisory Board are:
- Dr. Günther R. Adolf (former Vice President Pharmacology and Deputy Head of Oncology Research at Boehringer Ingelheim, Vienna, Austria),
- Prof. Dr. Bruce D. Cheson (Professor of Medicine & Deputy Chief, Division of Hematology and Oncology, Georgetown University Hospital, Washington D.C., USA),
- Dr. Sergio Quezada (Professorial Research Fellow and Group Leader, Immune Regulation and Tumor Immunotherapy, University College London Cancer Institute, London, UK), and
- Dr. Raymond W. Sweet (former Senior Director and Fellow, Biologics Research at Janssen, J&J, Pennsylvania, USA).
"It is a great pleasure to welcome our new Scientific Advisory Board members to MorphoSys," said Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Their strong drug discovery and development expertise in therapeutic fields of key interest to MorphoSys such as oncology, autoimmune and inflammatory diseases will perfectly support our ongoing and future discovery and development activities."
"We are excited to inaugurate a Scientific Advisory Board with highly experienced experts, who will support us in growing and maturing our proprietary pipeline of promising drug candidates," added Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "Their scientific and clinical insight and guidance will further help us to exploit the full potential of our portfolio."
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Associate Director Corporate Communications & IR
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
Media Release http://hugin.info/130295/R/2041087/761484.pdf
Source: MorphoSys AG